NeuroOne Medical Technologies Corporation (Nasdaq: NMTC), a medical technology company specializing in surgical solutions for neurological disorders, has scheduled the release of its financial results for the fiscal third quarter ended June 30, 2026. The announcement will be made before market open on Thursday, August 13, 2026, followed by an investor conference call and webcast at 8:30 a.m. Eastern time.
The company, based in Eden Prairie, Minnesota, aims to transform the surgical diagnosis and treatment of neurological conditions through its innovative electrode technology platform. The upcoming earnings call will provide stakeholders with an opportunity to review the company's financial performance, receive a corporate update, and participate in a question-and-answer session with management.
Investors and analysts can join the call by dialing 888-506-0062 (toll-free within the U.S.) or 973-528-0011 (international), using participant access code 549778. A live webcast will also be available via the company's investor relations website. Participants are advised to dial in at least five minutes before the scheduled start time to ensure timely access.
For those unable to attend the live event, a telephone replay will be accessible through Thursday, August 27, 2026, by calling 877-481-4010 (U.S.) or 919-882-2331 (international) with replay passcode 54304. Additionally, a webcast replay will be available on the same link through August 13, 2027.
NeuroOne's technology platform includes four FDA-cleared product families: Evo® Cortical Electrodes, Evo® sEEG Electrodes, OneRF® Ablation System (for brain), and OneRF® Trigeminal Nerve Ablation System. These products are designed to offer minimally invasive, high-definition, and high-precision solutions for neurological procedures. The company believes these innovations can reduce the number of hospitalizations and surgical procedures, lower healthcare costs, and improve patient outcomes by providing both diagnostic and therapeutic capabilities.
Beyond its current product portfolio, NeuroOne is actively engaged in research and development for drug delivery, basivertebral nerve ablation, and spinal cord stimulation programs. These initiatives underscore the company's commitment to expanding its offerings and addressing unmet needs in the neurological and spinal care markets.
The upcoming financial results will reflect the company's performance during a period of continued advancement in its product pipeline and commercial efforts. Investors and industry observers will be keen to assess the company's revenue growth, operational efficiency, and progress in achieving its strategic objectives. The conference call will offer insights into management's outlook and future plans, which could have implications for the company's stock performance and its competitive position in the medical technology sector.
NeuroOne's focus on improving surgical care for neurological disorders aligns with broader industry trends toward less invasive procedures and enhanced precision. As the company continues to develop and commercialize its technologies, its financial health and strategic direction will be closely monitored by investors, healthcare providers, and patients alike. The announcement of the third quarter results marks a key milestone in the company's fiscal calendar, providing a comprehensive view of its recent achievements and challenges.
